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Abstract The activation of the transcription factor NF-UB
often results in protection against apoptosis. In particular, pro-
apoptotic tumor necrosis factor (TNF) signals are blocked by
proteins that are induced by NF-UB such as TNFR-associated
factor 1 (TRAF1). Here we show that TRAF1 is cleaved after
Asp-163 when cells are induced to undergo apoptosis by Fas
ligand (FasL). The C-terminal cleavage product blocks the
induction of NF-UB by TNF and therefore functions as a
dominant negative (DN) form of TRAF1. Our results suggest
that the generation of DN-TRAF1 is part of a pro-apoptotic
amplification system to assure rapid cell death.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
The transcription factor NF-UB regulates the expression of
a diverse set of genes involved in immune function, di¡eren-
tiation and proliferation [1]. NF-UB activation conveys pro-
tection against cell death induced by growth factor with-
drawal, tumor necrosis factor (TNF) K and Fas ligand
(FasL) [2^6]. However, little is known about the mechanism
by which NF-UB provides protection against apoptosis,
although the transcriptional activation of survival genes is
believed to play a major role [3].
Death induced by TNF is most tightly regulated by NF-UB.
Modulation of the response in favor of NF-UB protects cells
from TNF-mediated apoptosis, failure to do so results in in-
creased cell death [2,3]. Intriguingly, TNF itself is an activator
of NF-UB, indicating the existence of a complex regulatory
loop [7]. Upon binding to TNF, TNFR1 binds the adaptor
protein TRADD which recruits caspase-8 via FADD leading
to apoptosis [8]. Alternatively, TRADD binds to the kinase
RIP, TNFR-associated factor 1 (TRAF1) and TRAF2, result-
ing in the degradation of the inhibitor of NF-UB, I-UB, fol-
lowed by the translocation of the transcription factor from the
cytoplasm into the nucleus. I-UB is degraded by proteasomes
upon phosphorylation of two serine residues by speci¢c ki-
nases, named I-UB kinases (IKKs). The importance of these
proteins in NF-UB signaling is illustrated by the analysis of
IKKL and NF-UB (RelA subunit) de¢cient mice, which die at
mid-gestation due to extensive apoptosis in the developing
liver [1,9,10].
TNF is therefore an interesting example of the activation,
by a single cytokine, of two con£icting pathways. It appears
that partial activation of the NF-UB pathway su⁄ces to in-
duce a positive modulatory loop which further increases NF-
UB signals, thus resulting in a potent blockade of the compet-
ing pro-apoptotic pathway. At least four NF-UB responsive
genes are involved in this survival ampli¢cation loop [3]: IAP-
1 and IAP-2 which block caspase activity [11], and TRAF1
and TRAF2 which are implicated in the NF-UB signaling
pathway [12]. Whether a similar positive modulatory loop
also exists for the pro-apoptotic pathway of TNF (and other
death receptors) is not known. It is justi¢able that, upon in-
duction of a weak pro-apoptotic signal, silencing of NF-UB
inhibitory signals would occur, allowing cell death to proceed
with maximal pace. Here we show that apoptosis results in a
caspase-dependent cleavage of TRAF1. TRAF1 processing
results in the generation of dominant negative (DN) frag-
ments that inhibit further NF-UB signals, thereby blocking
anti-apoptotic signals.
2. Materials and methods
2.1. Cell culture
The 293T human embryonic kidney (HEK) cells, BJAB Burkitt
lymphoma cells and HT1080 cells (¢brosarcoma cell line) were cul-
tured in Dulbecco’s modi¢ed Eagle’s medium supplemented with 10%
fetal calf serum (FCS) and penicillin/streptomycin (100 Wg/ml of each)
and grown in 5% CO2 at 37‡C. Jurkat and Raji cells were cultured in
RPMI supplemented as above.
2.2. Antibodies/reagents
Monoclonal antibodies used in immunoprecipitation and Western
blotting include: anti-Flag antibody (Kodak), anti-caspase-3 antibod-
ies (Transduction Laboratories), anti-caspase-8 antibody (PharMin-
gen), anti-TRAF1 antibody (H3, Santa Cruz), anti-VSV antibody
(P5D4, Sigma). Human recombinant ligands (TRAIL, FasL, TNFK)
were obtained from Alexis, Switzerland. Incubations with TRAIL and
FasL were performed in the presence of 1 Wg/ml anti-Flag M2 anti-
body. Caspase inhibitors were purchased from Alexis. Active caspase-
3, -6, -7 and -8 were kindly provided by Gay Salveson, San Diego,
CA, USA.
2.3. Expression vectors
Expression vectors for TRAF1, TRAF1(164^415), TRAF1Asp-
163Ala, TRAF1Asp225Ala were generated by PCR ampli¢cation/
PCR-based mutagenesis, and subcloned into pCR3-derived vectors
(Invitrogen) conferring an N-terminal and/or C-terminal Flag-tag.
The following plasmids were obtained from the indicated sources:
NF-UB luc, a dominant form of I-UB (I-UBmut) (V. Jongeneel, Epa-
linges, Switzerland), myc-TRADD (D.V. Goeddel, Tularik, San Fran-
cisco, CA, USA).
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2.4. Transfection
293T Cells were seeded at 4U105 in a 3.5 cm plate and transfected
by the calcium phosphate precipitation method. The precipitate was
left for 8 h, cells were collected 24 h after transfection, lysed in sodium
dodecyl sulfate (SDS) sample bu¡er by soni¢cation, and analyzed by
SDS^polyacrylamide gel electrophoresis (PAGE) and Western blot.
HT1080 cell lines expressing I-UBmut or TRAF1DN were established
as described [3].
2.5. Induction of TRAF1 or apoptosis
5U105 cells were incubated for the indicated times with TRAIL,
FasL and TNF. Incubations with TRAIL and FasL were performed
in the presence of 1 Wg/ml anti-Flag M2 antibody. Cells were har-
vested, washed one time with phosphate-bu¡ered saline (PBS), lysed
in SDS sample bu¡er by soni¢cation and analyzed by SDS^PAGE
and Western blot analysis. Alternatively, surviving cells were quanti-
¢ed with the Celltiter 96 AQ proliferation assay (Promega) following
the manufacturer’s instructions.
2.6. In vitro translation/caspase cleavage assay
In vitro translation of the TRAF1 wild-type and mutant forms was
carried out with the TNT Coupled Reticulocyte Lysate System (Prom-
ega) according to manufacturer’s instructions in the presence of
[35S]methionine (Amersham). Translations were incubated for 2 h in
20 mM PIPES, 100 mM NaCl, 1% sucrose, 10 mM dithiothreitol,
0.1% CHAPS and 0.1 mM EDTA, pH 7.2, at 37‡C in the presence
of caspase-3, -6, -7 or -8 as described [13]. Reaction mixtures were
subjected to SDS^PAGE, transferred to nitrocellulose and analyzed
by autoradiography.
2.7. Luciferase assay
293T Cells were co-transfected with 1 Wg NF-UB luciferase reporter
plasmid (NF-UB luc), 0.5 Wg pCMV L-gal (as an internal e⁄ciency
control) and 1 Wg of the indicated expression plasmids or empty vec-
tor. 24 h post-transfection, the cells were washed one time with PBS
and incubated for 5 h with 20 ng/ml TNFK in the absence of FCS.
Luciferase activities were determined using luciferase assay reagent
(Promega) as previously described [14].
3. Results
3.1. Cleavage of TRAF1 during apoptosis in 293T cells
While studying pro-apoptotic signaling pathways in
HEK293T cells, we observed that TRAF1 was cleaved from
the intact 51 kDa protein into a 27 kDa N-terminal fragment
when co-transfected with an apoptosis-inducing protein (Fig.
1A). This processing of TRAF1 was similarly detected when
apoptosis was triggered via the mitochondrial pathway (Bak)
or via pathways emanating from the cell surface through
death receptors, including Fas, TRAMP/DR-3 and TRAIL-
R1, or components of their signaling pathways (TRADD,
RIP) which induce cell death in a ligand-independent manner
when overexpressed [15]. Identical TRAF1 processing was
also observed when 293T cells were treated with recombinant
TRAIL and FasL (Fig. 1B). FasL-induced TRAF1 processing
was less e⁄cient, which is explained by the fact that 293T cells
are only moderately sensitive to FasL. Of the six TRAF pro-
teins identi¢ed thus far [12], this processing appeared to be
unique to TRAF1 as cleavage was not observed with TRAF2^
6 (data not shown). TRAF1 cleavage was e¡ectively blocked
by the general caspase inhibitor z-VAD-fmk, but not by other
protease inhibitors (data not shown). We therefore hypothe-
sized that TRAF1 cleavage might be caspase-mediated and to
this end, we mutated possible caspase cleavage sites in TRAF1
(Fig. 1C). While the Asp225Ala replacement had no e¡ect on
TRAF1 processing, the Asp163Ala mutation completely abol-
ished cleavage during apoptosis (Figs. 1D, 2B and data not
shown). All TRAFs contain a conserved TRAF domain at
their carboxyl-terminus, which is required for homo- and het-
ero-oligomerization of TRAFs, binding to the receptor and
for the interaction with other proteins [12]. The N-terminal
segment of most TRAFs is characterized by the presence of a
RING ¢nger domain, followed by a stretch of zinc ¢ngers.
TRAF1 is unique among the TRAFs in two regards (Fig. 1C).
First, it lacks the N-terminal RING ¢nger domain, and sec-
ond, its expression is not constitutive, but has to be induced
[16]. Cleavage at Asp-163 is predicted to separate the N-ter-
minal fragment of TRAF1 containing a zinc ¢nger from the
C-terminal TRAF domain (Fig. 1C).
3.2. TRAF1 cleavage by puri¢ed caspases in vitro
Comparison of the processing site in TRAF1 (LEVD/C)
with the cleavage speci¢cities of various caspases [17] indi-
cated that it resembled the substrate sites of caspase-8 and
caspase-6. We therefore performed cleavage experiments using
in vitro translated and 35S-labeled TRAF1. Incubation of
Fig. 1. TRAF1 cleavage during apoptosis. (A) 293T Cells were
transfected with 3 Wg of a plasmid encoding the indicated apoptosis-
inducing proteins together with 0.3 Wg FlagTRAF1. Processing of
TRAF1 was revealed by immunoblotting using an anti-Flag anti-
body. (B) 293T Cells were transfected with 0.3 Wg FlagTRAF1 dur-
ing 1 day, treated for an additional 12 h with recombinant cross-
linked soluble FasL (FasL, 1 Wg/ml) or soluble TRAIL (100 ng/ml)
and then analyzed as above. (C) Diagram of human TRAF1, indi-
cating the caspase cleavage site (163/164), the zinc ¢nger region (Z)
and the TRAF domain (TRAF) which includes a coiled-coil domain
(stippled box). (D) As (A), but 293T cells were transfected with the
FlagTRAF1 mutant (Asp163Ala) construct.
FEBS 23350 15-2-00
M. Irmler et al./FEBS Letters 468 (2000) 129^133130
TRAF1 with a panel of puri¢ed recombinant caspases at dif-
ferent concentrations resulted in the generation of two cleav-
age products (Fig. 2A). The N-terminal fragment migrated
slower than expected (apparent molecular weight: 26 kDa,
calculated: 19 kDa), whereas the C-terminal fragment mi-
grated as predicted (29 kDa) and was not further processed
by either caspase (Fig. 2B and data not shown). In vitro,
caspases-3, -6 and most e⁄ciently caspase-8 cleaved TRAF1,
whereas TRAF1 was not a substrate for caspase-7. The mu-
tant TRAF1 (Asp163Ala) was not processed by either caspase
(Fig. 2C), again demonstrating that Asp-163 is the only cas-
pase cleavage site present in TRAF1.
3.3. Cleavage of TRAF1 is an early event during
FasL-mediated apoptosis
TRAF1 expression is known to be restricted to certain tis-
sues and to be induced through the activation of NF-UB [16].
We therefore screened several cell lines for TRAF1 expression.
TRAF1 was strongly induced in HT1080 cells by TNF, and
weakly in HeLa cells (Fig. 3A) as reported previously [3,16].
Burkitt lymphoma-derived Raji and BJAB cells constitutively
express TRAF1 (Fig. 3A). As both Raji and BJAB cells are
also susceptible to Fas triggering, we chose these cells to study
conversion of TRAF1. FasL induces apoptosis by the sequen-
tial activation of caspase-8, caspase-3 and other caspases
which ¢nally results in the cleavage of a wide range of cellular
substrates. The induction of apoptosis in BJAB cells led to the
activation of caspase-8 following 40^60 min as shown by the
disappearance of the caspase-8 precursor (Fig. 3B). The
TRAF1 cleavage product was already detected following
20^40 min, at the same time, when the subunits of active
caspase-3 appeared. In Raji cells, FasL-induced TRAF1 cleav-
age was observed before caspase-3 activation (Fig. 3C), sug-
gesting that TRAF1 cleavage occurs early during signal trans-
duction by activated caspase-8. This is supported by the
observation (Fig. 3D) that the addition of either the broad
range caspase inhibitor z-VAD-fmk or the caspase-8 inhibitor
IETD-fmk completely blocked TRAF1 conversion in 293T
Fig. 2. Processing of TRAF1 by caspases in vitro. (A) In vitro
translated FlagTRAF1 was incubated with decreasing concentrations
of caspase-3, -6, -7 or -8 (0.5, 0.05 and 0.005 WM). (B) Various in
vitro translated TRAF1 constructs (TRAF1 with N- and C-terminal
Flag; TRAF1(164^416) with N- or C-terminal Flag; TRAF1(Asp-
225Ala)) were incubated in the presence or absence of caspase-8
(0.5 WM). (C) In vitro translated mutant FlagTRAF1(Asp163Ala)
was incubated with decreasing concentrations of caspase-3, -6, -7 or
-8 (0.5 and 0.05 WM). Reaction mixtures were incubated for 2 h at
37‡C, and then analyzed by SDS^PAGE, transferred onto nitrocel-
lulose and subsequently autoradiographed.
Fig. 3. Expression of TRAF1 in various cell lines and time course
of TRAF1 cleavage during FasL-induced apoptosis. (A) Various cell
lines (106 cells) were incubated for 6 h in the presence or absence of
TNF (30 ng/ml) as indicated and assayed for TRAF1 expression by
immunoblotting. (B) BJAB cells and (C) Raji cells were treated with
cross-linked sFasL (300 ng/ml) for the indicated times. The general
caspase inhibitor z-VAD-fmk was added as indicated. Processing of
TRAF1, caspase-3 and caspase-8 was assessed by Western blot anal-
ysis of cell lysates using the appropriate antibodies. (D) Flag-
TRAF1-transfected 293T cells were treated with cross-linked FasL
for 12 h (see Fig. 1B) in the presence of various caspase inhibitors.
TRAF1 was detected using the anti-Flag M2 antibody.
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cells, whereas only partial inhibition was observed when the
caspase-3 inhibitor DEVD-fmk was included.
3.4. The C-terminal cleavage product functions as a DN form
to inhibit TNF-induced activation of NF-UB
Cleavage of TRAF1 occurs at the Asp-163 residue, which is
located approximately 30 amino acids upstream of the TRAF
domain. The C-terminal cleavage product of TRAF1 there-
fore closely resembles the DN versions of TRAF1 and other
TRAFs, which only contain the C-terminal TRAF domain
[16]. We therefore reasoned that cleavage of TRAF1 could
lead to a block of TRAF1-dependent activation of NF-UB,
and thus to the triggering of a pro-apoptotic loop. We trans-
fected 293T cells with the truncated TRAF1, corresponding to
the fragment generated in apoptotic cells. The treatment with
TNF of vector-transfected cells induced a strong activation of
NF-UB which was blocked by the expression of TRAF1(164^
516) in a similar manner to other inhibitors of TNF-mediated
NF-UB activation, including TRAF2DN and a DN form of I-
UB (Fig. 4).
3.5. NF-UB activation in HT1080 results in TRAF1 induction
and protection from FasL-induced apoptosis which is
reverted when NF-UB signals are blocked
HT1080 ¢brosarcoma cells have been widely used to study
the regulation of TNF-induced cell death. The parental cell
line is resistant to TNF-induced apoptosis and instead acti-
vates signals leading to NF-UB activation, whereas cell death
ensues if NF-UB activation is inhibited [3]. We therefore chose
this cell line to study the in£uence of NF-UB signals on FasL-
induced apoptosis and to investigate the signi¢cance of
TRAF1 cleavage.
In contrast to TNF [3], the parental cell line was not resis-
tant to FasL (Fig. 5). Activation of caspase-3 was observed 3
h after addition of the ligand. However, preincubation of the
HT1080 cells with TNF for 6 h, which resulted in a massive
NF-UB activation as evidenced by TRAF1 upregulation, con-
veyed resistance to FasL (Fig. 5A). Nevertheless, Fas resis-
tance remained only partial, due to caspase-3 activation and
as a consequence TRAF1 cleavage which was clearly observed
after 24 h.
Having established that HT1080 cell death by Fas can be
modulated by NF-UB, we investigated whether the complete
blockade of the NF-UB signals would also lead to increased
death as has been shown for TNF [3]. In agreement with the
published results, HT1080 cells stably expressing a non-de-
Fig. 4. Transcription factor NF-UB is blocked by the C-terminal
TRAF1 cleavage product. 293T Cells were transfected with Flag-
TRAF1(164^416) or with DN forms of other proteins implicated in
the NF-UB pathway. 24 h after transfection, cells were treated with
TNF (10 ng/ml) for 6 h and NF-UB activity was measured by a lu-
ciferase reporter assay. Values shown are averages of four represen-
tative experiments in which each transfection was carried out in du-
plicate.
Fig. 5. (A) Activation of NF-UB signaling pathway prevents rapid
Fas-mediated apoptosis. HT1080 cells were pretreated or not pre-
treated with TNF (30 ng/ml) for 6 h and then incubated with cross-
linked FasL (300 ng/ml) for 3 h or overnight (o/n) in the presence
or absence of z-VAD-fmk. Cell lysates were analyzed for processing
of caspase-3 and TRAF1 as described in Fig. 3. (B) DN-
TRAF1(164^415) promotes death ligand-induced apoptosis. HT1080
¢brosarcoma cells were stably transfected with the FlagTRAF1(164^
415) expression plasmid and expression of FlagTRAF1(164^415)
was analyzed in several clones by immunoblotting using the M2
anti-FLAG antibody. (C) A representative HT1080-TRAF1DN
clone, and as controls parental HT1080 cells and HT1080 cells ex-
pressing a DN mutant form of I-UB (I-UBmut), were incubated with
TNF (100 ng/ml), FasL (100 ng/ml) or TRAIL (100 ng/ml), respec-
tively, and the viability of cells was analyzed. Other clones analyzed
showed similar resistance to death ligands.
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gradable inhibitor of NF-UB (I-UBmut), thereby blocking NF-
UB function, were sensitive to TNF killing. The same mutant
cells also showed increased sensitivity to FasL and TRAIL
(Fig. 5C). Thus, complete suppression of NF-UB activity ren-
ders HT1080 cells more sensitive to several death ligands.
To determine whether the TRAF1(164^415) fragment,
which in transient overexpression experiments blocked NF-
UB activation by TNF almost as e⁄ciently as I-UBmut (see
Fig. 4), would also sensitize HT1080 cells, several clones were
established that stably express TRAF1(164^415) (Fig. 5B).
Indeed, all HT1080-TRAF1DN cells analyzed were sensitive
to TNF, and increased sensitivity to FasL and TRAIL was
also observed (Fig. 5C). However, if compared to the
HT1080-I-UBmut cells, sensitization by TRAF1DN was less
e⁄cient.
4. Discussion
The involvement of NF-UB activation in regulating apop-
tosis has been documented by several groups. Inhibition of
NF-UB nuclear translocation increases the susceptibility of
cells to undergo apoptosis by TNF, FasL, ionizing radiation,
cancer therapeutic drugs and growth factor withdrawal [2^
4,6].
Here we show that at least one of the proteins that is crucial
in the TNF anti-apoptotic response is inactivated during Fas-
mediated apoptosis, i.e. TRAF1. TRAF1 has a direct anti-
apoptotic e¡ect. TRAF1 was shown to directly associate
with TNFR2, CD30, 4-1BB [18], Ox40[18], HVEM [19] and
LMP-1 [20]. In addition to forming homodimers and hetero-
dimers with TRAF2, TRAF1 has been shown to directly in-
teract with TRADD [21], I-TRAF [22], TRIP [23], A20 [24], c-
IAP-1, c-IAP-2 [25], FLIP [26], RIP [27], CARMEN/Bcl-10
[28], CARDIAK/RIP2 [29,30] and NIK [31]. The signi¢cance
of these interactions is not clear in many cases, but the anti-
apoptotic nature of most interaction partners is in accordance
with published data on TRAF1 function. TRAF1 transgenic
mice show a defect in antigen-induced apoptosis of CD8 T
cells [32] and TRAF1 is part of the NF-UB-induced anti-apop-
totic response [3].
Thus, the generation of a DN form of TRAF1 will lead to
the impairment of an anti-apoptotic pathway controlled by
NF-UB and will ultimately result in a rapid cell death, thus
avoiding the situation that a cell is half dead and half alive.
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